Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

Cancer Chemotherapy and Pharmacology
George P StathopoulosE Dimou

Abstract

Based on previous experience, we combined topotecan with paclitaxel (weekly administration) in patients with non-small-cell lung cancer (NSCLC). Our primary objective was to determine the response rate and survival and our secondary objective, the safety of the regimen. From October 2003, until March 2005, 45 patients all with histologically or cytologically confirmed NSCLC were enrolled. All patients were chemotherapy and radiotherapy naive. Both agents were infused on day 1 of every week once for three consecutive weeks, every 28 days. Three infusions were considered as one course. The treatment plan was to give three courses (nine infusions) and then to evaluate the response. Topotecan (1.75 mg/m2) was infused for 30 min and paclitaxel (70 mg/m2) for 90 min; these doses had been established as the maximum tolerated dose in a previous phase I-II trial. Eighteen/45 (40%) patients responded, 2 (4.4%) complete responses and 16 (35.6%) partial responses. Twenty-one (46.7%) patients had stable disease, and 6 (13.3%) disease progression. The median duration of response was 8 months and median time to tumor progression 9 months. Grade 3 and 4 neutropenia was observed in two patients (in these two patients, the dose of both drugs was...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A DepierreJ Clavier
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L CrinòM Tonato
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F OshitaN Saijo
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M T HuizingJ H Beijnen
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W AkerleyL Leone
Aug 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J D HainsworthF A Greco
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V GeorgouliasJ Vlachonicolis
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R V IaffaioliA Illiano
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C P BelaniM J Egorin
Jun 4, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FrasciG Comella
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D PectasidesA Athanassiou
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V LorussoM De Lena
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V A MillerM G Kris
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FrasciM De Lena
Jul 14, 2001·The New England Journal of Medicine·D J SargentR L Schilsky
Oct 13, 2001·The New England Journal of Medicine·D J SargentG Francini
Apr 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GiacconeA Fandi
May 6, 2004·Cancer Chemotherapy and Pharmacology·George P StathopoulosDimosthenis V Skarlos
Jun 19, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G P StathopoulosA Gerogianni
Oct 13, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Giaccone

❮ Previous
Next ❯

Citations

Feb 13, 2007·Journal of Bioenergetics and Biomembranes·Dao M Nguyen, Mustafa Hussain
Jan 27, 2007·Current Oncology Reports·Cecilia MacCallum, Heidi H Gillenwater
Dec 17, 2009·Anti-cancer Drugs·George P StathopoulosMichael Vaslamatzis
Jan 12, 2021·Frontiers in Cell and Developmental Biology·Zi-Ning LeiZhe-Sheng Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.